About Madrigal Pharmaceuticals (NASDAQ:MDGL)
Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Industry, Sector and Symbol
Trailing P/E Ratio-47.7125984251969
Forward P/E Ratio-37.40
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$13.02 per share
Price / Book9.31
Return on Equity-37.46%
Return on Assets-34.28%
Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions
What is Madrigal Pharmaceuticals' stock symbol?
Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."
How were Madrigal Pharmaceuticals' earnings last quarter?
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) released its quarterly earnings results on Tuesday, March, 13th. The biopharmaceutical company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.03. View Madrigal Pharmaceuticals' Earnings History.
Where is Madrigal Pharmaceuticals' stock going? Where will Madrigal Pharmaceuticals' stock price be in 2018?
5 brokerages have issued twelve-month price targets for Madrigal Pharmaceuticals' stock. Their forecasts range from $125.00 to $210.00. On average, they expect Madrigal Pharmaceuticals' share price to reach $166.50 in the next twelve months. View Analyst Ratings for Madrigal Pharmaceuticals.
Who are some of Madrigal Pharmaceuticals' key competitors?
Some companies that are related to Madrigal Pharmaceuticals include ACADIA Pharmaceuticals (ACAD), Clovis Oncology (CLVS), Halozyme Therapeutics (HALO), Evotec (EVTCY), Puma Biotechnology (PBYI), China Biologic Products (CBPO), Amicus Therapeutics (FOLD), AnaptysBio (ANAB), Global Blood Therapeutics (GBT), Ascendis Pharma A/S (ASND), arGEN-X BV (ARGX), Immunomedics (IMMU), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), Spark Therapeutics (ONCE), Horizon Pharma (HZNP), The Medicines (MDCO) and Crispr Therapeutics (CRSP).
Who are Madrigal Pharmaceuticals' key executives?
Madrigal Pharmaceuticals' management team includes the folowing people:
- Paul A. Friedman M.D., Chairman of the Board, Chief Executive Officer
- Rebecca A. Taub M.D., Founder, Chief Medical Officer, Executive Vice President, Research & Development and Director
- Marc R. Schneebaum, Chief Financial Officer, Senior Vice President
- Frederick B. Craves Ph.D., Lead Independent Director
- Kenneth M. Bate, Independent Director
- Keith R. Gollust, Independent Director
- Richard S. Levy M.D., Independent Director
- David V. Milligan Ph.D., Independent Director
Has Madrigal Pharmaceuticals been receiving favorable news coverage?
News stories about MDGL stock have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Madrigal Pharmaceuticals earned a media sentiment score of 0.06 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 45.95 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Madrigal Pharmaceuticals' major shareholders?
Madrigal Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Citadel Advisors LLC (2.72%), Rock Springs Capital Management LP (2.44%), BlackRock Inc. (1.50%), Victory Capital Management Inc. (1.46%), Jennison Associates LLC (1.46%) and Perceptive Advisors LLC (1.35%). View Institutional Ownership Trends for Madrigal Pharmaceuticals.
Which institutional investors are selling Madrigal Pharmaceuticals stock?
Which institutional investors are buying Madrigal Pharmaceuticals stock?
MDGL stock was acquired by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Jennison Associates LLC, Perceptive Advisors LLC, Victory Capital Management Inc., Bogle Investment Management L P DE, Rock Springs Capital Management LP, EAM Investors LLC and Ascend Capital LLC. View Insider Buying and Selling for Madrigal Pharmaceuticals.
How do I buy shares of Madrigal Pharmaceuticals?
Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Madrigal Pharmaceuticals' stock price today?
One share of MDGL stock can currently be purchased for approximately $121.19.
How big of a company is Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals has a market capitalization of $1.62 billion. The biopharmaceutical company earns $-31,150,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Madrigal Pharmaceuticals employs 8 workers across the globe.
How can I contact Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 484-380-9263 or via email at [email protected]
MarketBeat Community Rating for Madrigal Pharmaceuticals (MDGL)MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Madrigal Pharmaceuticals (NASDAQ:MDGL) Earnings History and Estimates Chart
Madrigal Pharmaceuticals (NASDAQ MDGL) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Madrigal Pharmaceuticals (NASDAQ:MDGL) Earnings Estimates
Current Year EPS Consensus Estimate: $-3.24 EPS
Next Year EPS Consensus Estimate: $-4.86 EPS
Dividend History for Madrigal Pharmaceuticals (NASDAQ:MDGL)
No dividend announcements for this company have been tracked by MarketBeat.com
Madrigal Pharmaceuticals (NASDAQ MDGL) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 66.40%
Institutional Ownership Percentage: 35.98%
Madrigal Pharmaceuticals (NASDAQ MDGL) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/23/2017||Richard S Levy||Director||Buy||2,000||$16.12||$32,240.00||7,200|| |
|8/22/2017||Richard S Levy||Director||Buy||3,550||$16.12||$57,226.00||3,640|| |
|8/21/2017||Richard S Levy||Director||Buy||3,550||$15.88||$56,374.00||900|| |
|12/14/2015||Keith R Gollust||Director||Sell||600,000||$0.35||$210,000.00||401,764|| |
|12/9/2015||Keith R Gollust||Director||Sell||745,892||$0.38||$283,438.96||401,764|| |
|12/8/2015||Bruce Kovner||Director||Sell||1,523,346||$0.37||$563,638.02||3,092,677|| |
|12/3/2015||Bruce Kovner||Director||Sell||1,430,753||$0.43||$615,223.79||3,092,677|| |
|11/30/2015||Bruce Kovner||Director||Sell||3,078,820||$0.48||$1,477,833.60||3,092,677|| |
|11/24/2015||Bruce Kovner||Director||Sell||1,173,582||$0.44||$516,376.08||3,092,677|| |
|11/20/2015||Bruce Kovner||Director||Sell||1,513,088||$0.49||$741,413.12||3,092,677|| |
|11/17/2015||Bruce Kovner||Director||Sell||1,223,936||$0.43||$526,292.48||3,092,677|| |
|11/12/2015||Bruce Kovner||Director||Sell||5,436,673||$0.55||$2,990,170.15||3,092,677|| |
|11/10/2015||Keith R Gollust||Director||Sell||188,322||$0.55||$103,577.10||401,764|| |
|4/6/2015||Robert N Wilson||Director||Buy||50,000||$1.75||$87,500.00|| |
|9/30/2014||Bruce Kovner||Director||Buy||300,000||$3.08||$924,000.00|| |
|4/11/2014||Bruce Kovner||Director||Buy||1,250,000||$4.01||$5,012,500.00||3,048,666|| |
|11/13/2013||Bruce Kovner||Director||Buy||5,000,000||$3.75||$18,750,000.00||6,130,330|| |
|11/13/2013||Safi Bahcall||CEO||Buy||20,000||$3.75||$75,000.00||2,053,135|| |
|6/28/2013||Safi R Bahcall||CEO||Buy||10,000||$5.03||$50,300.00|| |
|6/27/2013||Bruce Kovner||Director||Buy||150,000||$4.71||$706,500.00|| |
|6/26/2013||Bruce Kovner||Director||Buy||500,000||$4.53||$2,265,000.00|| |
|6/21/2013||Bruce Kovner||Director||Buy||250,000||$4.39||$1,097,500.00|| |
|6/21/2013||Safi R Bahcall||CEO||Buy||20,000||$4.12||$82,400.00|| |
|6/18/2013||Bruce Kovner||Director||Buy||200,000||$4.00||$800,000.00|| |
|6/14/2013||Safi R Bahcall||CEO||Buy||10,000||$4.06||$40,600.00|| |
|6/6/2013||Bruce Kovner||Director||Buy||2,000,000||$4.64||$9,280,000.00|| |
|6/6/2013||Safi R Bahcall||CEO||Buy||10,000||$4.04||$40,400.00|| |
|6/5/2013||Vojo Vukovic||SVP||Buy||10,000||$4.58||$45,800.00|| |
|6/4/2013||Robert N Wilson||Director||Buy||10,000||$5.00||$50,000.00|| |
|11/14/2012||Bruce Kovner||Director||Buy||37,700||$6.91||$260,507.00|| |
|11/12/2012||Safi R Bahcall||CEO||Buy||10,000||$7.12||$71,200.00|| |
Madrigal Pharmaceuticals (NASDAQ MDGL) News Headlines
Madrigal Pharmaceuticals (NASDAQ:MDGL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Madrigal Pharmaceuticals (NASDAQ:MDGL) Income Statement, Balance Sheet and Cash Flow Statement
Madrigal Pharmaceuticals (NASDAQ MDGL) Stock Chart for Tuesday, March, 20, 2018